Anke Bio's Investee Company's CAR-T Therapy PA3-17 Injection Enters Pivotal Phase II Clinical Trial

AI ExpressOn September 17,ANKEBIOAnnouncement: Bo Shengji Medicine Science and Technology (Suzhou) Co., LTD and Bo Shengji Anke Cell Technology Co., LTD, subsidiaries of ANKEBIO, have received the minutes of the Phase II communication meeting for PA3-17 injection issued by the Center for Drug Evaluation of the National Medical Products Administration. The minutes indicate that the applicant has been approved to conduct the pivotal Phase II clinical trial for PA3-17 injection. Notably, PA3-17 injection is the world's first self-developed autologous CAR-T cell therapy product targeting CD7 to receive approval for clinical trials as a new drug. This product is mainly used for treating adult patients with relapsed or refractory CD7-positive hematological lymphatic system malignancies.

(AI-generated article, for reference only)